Consensus Gilead Sciences, Inc. Buenos Aires S.E.

Stocks

GILD

ARBCOM4601C4

Pharmaceuticals

End-of-day quote Buenos Aires S.E. 2026-09-08			5-day change	1st Jan Change
58,200.00 ^ARS	-3.48%		-2.18%	+24.20%

09-08	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead	MT
09-08	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead	DJ

5e.QSCpTdJgsr8is_Lp7mk0nKPJDG_eb3Cey0dp8YwAxAA.KnrvDJ4p_8lK5ZeOtht19OuRbzCZVgbR8nQCgOhD8EU3Qdk5mQ_Y6lbnow~573a47072d6ee4e8af3664cea26a6630

Analysts' recommendations: Gilead Sciences, Inc.

08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07-07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07-07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
07-06	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
07-06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
06-08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
05-20	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
05-19	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
05-11	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
05-11	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
05-08	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
05-08	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
05-08	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT
04-28	Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+14.46%
	JOHNSON & JOHNSON					+0.15%
	ABBVIE INC.					+7.85%
	ROCHE HOLDING AG					+5.04%
	NOVARTIS AG					+0.28%
	ASTRAZENECA PLC					+30.49%
	AMGEN INC.					-11.09%
	NOVO NORDISK A/S					+3.46%
	GILEAD SCIENCES, INC.					+4.25%
	Average					+6.10%
	Weighted average by Cap.					+7.34%